BRD4 and nonpapillary renal cell carcinoma: In conclusion, BRD4 expression may be a potential prognostic marker in ccRCC, and JQ1, as a BRD4 inhibitor, significantly inhibited cancer cell aggressiveness both in vitro and in vivo in sunitinib-sensitive and -resistant ccRCC.